Bridgeway Capital Management LLC Boosts Stock Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSI)

Bridgeway Capital Management LLC increased its stake in TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) by 333.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 65,000 shares of the company's stock after purchasing an additional 50,000 shares during the period. Bridgeway Capital Management LLC owned approximately 0.21% of TriSalus Life Sciences worth $326,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Renaissance Technologies LLC bought a new position in TriSalus Life Sciences in the 4th quarter valued at $67,000. Northern Trust Corp raised its holdings in shares of TriSalus Life Sciences by 22.7% during the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company's stock valued at $161,000 after buying an additional 5,936 shares in the last quarter. Bank of America Corp DE grew its position in TriSalus Life Sciences by 120,471.6% during the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company's stock worth $894,000 after acquiring an additional 178,298 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in TriSalus Life Sciences by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 204,137 shares of the company's stock worth $1,023,000 after acquiring an additional 3,710 shares during the last quarter. Institutional investors own 2.58% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on TLSI shares. Roth Mkm restated a "buy" rating and set a $11.00 price target on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Lake Street Capital initiated coverage on TriSalus Life Sciences in a research note on Thursday, February 13th. They issued a "buy" rating and a $10.00 price objective for the company. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research report on Friday, March 28th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $10.93.

TriSalus Life Sciences Trading Up 0.6%

Shares of NASDAQ TLSI traded up $0.03 during trading on Friday, reaching $5.14. 34,589 shares of the company traded hands, compared to its average volume of 42,983. TriSalus Life Sciences, Inc. has a 12-month low of $3.50 and a 12-month high of $10.17. The stock has a market cap of $165.88 million, a P/E ratio of -2.06 and a beta of 0.50. The firm's fifty day simple moving average is $5.40 and its 200 day simple moving average is $5.01.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.13). The firm had revenue of $9.17 million during the quarter, compared to analyst estimates of $9.04 million. During the same quarter in the prior year, the company posted ($0.60) EPS. As a group, research analysts expect that TriSalus Life Sciences, Inc. will post -1.55 EPS for the current year.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.